Company: SMNR
Filing Date: 2025-08-15
Form Type: 10-Q
Source: 0001213900-25-077047
Chunk: 35

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-15
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
594,042)
  
    Net loss including accretion of temporary equity 
    $(405,826) 
    $(724,591) 
    $(341,245) 
    $(880,800)

18

Denali Capital Acquisition Corp.

Notes to Unaudited Consolidated Financial Statements

    For the Three Months Ended  
    For the Three Months Ended 

    June 30, 2025  
    June 30, 2024 

    Non-  
       
    Non- 

    Redeemable  
    Redeemable  
    Redeemable  
    Redeemable 

    Common  
    Common  
    Common  
    Common 

    Stock  
    Stock  
    Stock  
    Stock 
  
    Basic and diluted net income (loss) per share: 

    Numerators: 

    Allocation of net loss including accretion of temporary equity 
    $(18,310) 
    $(387,516) 
    $(217,783) 
    $(123,462)
  
    Accretion of temporary equity to redemption value 
     20,704  
     -  
     790,157  
     - 
  
    Allocation of net income/(loss) 
    $2,394  
    $(387,516) 
    $572,374  
    $(123,462)

    Denominators: 

    Weighted-average shares outstanding 
     121,552  
     2,572,500  
     4,537,829  
     2,572,500 
  
    Basic and diluted net income/ (loss) per share 
    $0.02  
    $(0.15) 
    $0.13  
    $(0.05)

    For the Six Months Ended  
    For the Six Months Ended 

    June 30, 2025  
    June 30, 2024 

    Non-  
       
    Non- 

    Redeemable  
    Redeemable  
    Redeemable  
    Redeemable 

    Common  
    Common  
    Common  
    Common 

    Stock  
    Stock  
    Stock  
    Stock 
  
    Basic and diluted net income (loss) per share: 

    Numerators: